Trial Profile
Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2023
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NIRA-PANC
- 06 Jun 2023 Results assessing efficacy of niraparib monotherapy patients with locally advanced and metastatic PC harboring DNA repair defects, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 18 May 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Apr 2021 Planned primary completion date changed from 28 Jun 2021 to 28 Jun 2023.